Emily B. Walling
Expertise in
10
conditions
Expertise in
10
conditions
1540 E Hospital Dr, Floor 7 Reception C, 
Ann Arbor, MI 

Overview

Emily B. Walling MD, MPHS is a Clinical Assistant Professor in the Division of Hematology/Oncology, Department of Pediatrics. Dr. Walling received her bachelor's degree from the University of Wisonsin-Madison and her medical degree from the University of Toledo. Following residency training in pediatrics at the Medical College of Wisconsin, Dr. Walling completed her fellowship training in pediatric hematology-oncology at Washington University where she earned her master's degree in population health sciences. Dr. Walling joined the faculty at Michigan in 2016. She founded and is the co-medical director of the Michigan Medicine Adolescent and Young Adult Oncology Program.

Dr. Walling is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Hereditary Neuroblastoma, Neuroblastoma, Osteosarcoma, and Bone Marrow Aspiration.

Dr. Walling is board certified in Pediatric Hematology-Oncology and Pediatrics. She is actively involved in clinical research, co-authoring 24 peer reviewed articles and participating in 6 clinical trials.

Graduate Institution

University Of Toledo College Of Medicine, 2010

Residency

Medical College of Wisconsin, Pediatrics, 2013

Specialties

Pediatrics

Licenses

Pediatrics in MI

Board Certifications

Pediatric Hematology-Oncology
Pediatrics

Fellowships

Washington University, Pediatric Hematology/Oncology, 2016

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 6 Less Insurance Carriers -

Locations

C. S. Mott Children's Hospital
1540 E Hospital Dr, Floor 7 Reception C, Ann Arbor, MI 48109

Additional Areas of Focus

Dr. Walling has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
View 4 Less Clinical Trials
Similar Doctors
Expertise in
31
conditions
Expertise in
31
conditions

C. S. Mott Children's Hospital

1540 E Hospital Dr, Floor 7 Reception C, 
Ann Arbor, MI 
 (0.2 miles away)
Languages Spoken:
English

Kelly Walkovich is a Pediatrics provider practicing medicine in Ann Arbor, Michigan. Dr. Walkovich is highly rated in 31 conditions, according to our data. Her clinical expertise encompasses Hemophagocytic Lymphohistiocytosis, Infantile Neutropenia, Non-Langerhans-Cell Histiocytosis, and Histiocytosis.

Expertise in
5
conditions
Expertise in
5
conditions

C. S. Mott Children's Hospital

1540 E Hospital Dr, Floor 7 Reception C, 
Ann Arbor, MI 
 (0.2 miles away)
Languages Spoken:
English

Dr. Steven Pipe is a Professor and the Laurence A. Boxer Research Professor of Pediatrics and Professor of Pathology at the University of Michigan, Ann Arbor, Michigan, USA. He is the medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory. His clinical interests include bleeding and thrombotic disorders and congenital vascular anomalies. Dr Pipe also directs a basic research lab investigating coagulation factor VIII and the molecular mechanisms of hemophilia A. He has been actively involved in clinical trials with novel therapeutics for hemophilia including gene therapy. He was the 2015 recipient of the Leadership in Research Award from the National Hemophilia Foundation. He has served on the Board of Directors for the Hemostasis and Thrombosis Research Society, as Chair of the Board of Directors for the American Thrombosis and Hemostasis Network and currently as Chair of the Medical and Scientific Advisory Committee to the National Hemophilia Foundation. Dr. Pipe is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Hemophilia A, Hemophilia B, Blood Clots, and Von Willebrand Disease (VWD).

Expertise in
33
conditions
Oncology | Pediatrics | Internal Medicine
Expertise in
33
conditions
Oncology | Pediatrics | Internal Medicine

Rogel Cancer Center

1500 E Medical Center Dr, Floor B1 Reception A, 
Ann Arbor, MI 
 (0.2 miles away)
Languages Spoken:
English
Offers Telehealth

Dr. Francis Worden received his medical degree from the Indiana University School of Medicine in 1993. Prior to attending medical school, he worked as a registered pharmacist at a large community hospital in Indianapolis. In 1997, Dr. Worden completed a combined residency in internal medicine and pediatrics at the Detroit Medical Center and finished a medical oncology/hematology fellowship at the University of Michigan. In July 2000, Dr. Worden joined the faculty at the University of Michigan Rogel Cancer Center, where he is currently working as a clinical investigator with both the multidisciplinary head and neck oncology team and the multidisciplinary lung cancer team. Dr. Worden's research interests include organ preservation in head and neck cancer and endocrine oncology. He is the Nancy Wigginton Oncology Research Professor of Thyroid Cancer. Avid competitive swimmer ; cyclist and runner. Dr. Worden is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Thyroid Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). Dr. Worden is board certified in Medical Oncology.

Frequently Asked Questions about Dr. Emily B. Walling

How do I make an appointment with Dr. Emily B. Walling?

You can book an appointment with Dr. Emily B. Walling by calling their office at 734-936-9814. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Emily B. Walling a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Emily B. Walling is classified as an Advanced expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Emily B. Walling specialize in?

While Dr. Emily B. Walling is a Pediatrics, they have specific expertise in Acute Lymphoblastic Leukemia (ALL), Hereditary Neuroblastoma, and Neuroblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Emily B. Walling participate in research or clinical trials?

Yes. Dr. Emily B. Walling has published 24 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Dr. Emily B. Walling's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Emily B. Walling accept my insurance?

Dr. Emily B. Walling accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 734-936-9814 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Walling's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 19 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile